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In dogs, digit squamous cell carcinoma (SCC) is uncommon. Clinical signs are frequently
underestimated, leading to a diagnostic delay. The purpose of this retrospective study
was to report our experience regarding the clinical presentation, diagnostic work-up,
treatment and outcome of 79 client-owned dogs with SCC of the digit. The greatest
majority (84.8%) of dogs was dark-coated. Schnauzers represented approximately one
third of the study population, and had a poorer outcome compared with other breeds.
The majority of SCCs occurred in the front limbs (61%), and bone lysis was frequently
observed (92.4%). Approximately 9% of dogs had involvement of multiple digits, and this
was associated with a shorter time to progression (TTP; P = 0.047). Similarly, a duration
of clinical signs >90 days was associated with a shorter TTP (P = 0.02). Regional lymph
nodemetastases were documented in 17.7% of dogs at admission and were significantly
associated with tumor-related death (P < 0.001). At presentation, none of the dogs had
evidence of distant metastasis. Digit amputation achieved adequate local tumor control
in the majority of cases. Adjuvant chemotherapy and radiation therapy were carried out
in 21.5% of cases, with uncertain benefit. Due to the relatively non-aggressive clinical
behavior of digit SCC, chemotherapy should only be offered in the case of metastatic
disease. Approximately one fourth of dogs developed de novo SCCs during the follow-
up. Careful examination of the digits should be encouraged in breeds considered at high
risk and in dogs with a previous history of digital SCC.
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INTRODUCTION
Cancer of the digits is considered to be uncommon in dogs, with
squamous cell carcinoma (SCC) representing the main histotype
(1, 2).
While exposure to ultraviolet radiation of poorly pigmented
skin has been associated with the cutaneous form of canine
and feline SCC, no predisposing factors have been described
for digital SCCs (3). In humans, Papillomaviruses (PVs) are
an established cause of cancer (4), and there is accumulating
evidence that theymay be responsible for the development of oral
and cutaneous SCCs in cats (5, 6). In this regard, several studies
have investigated the relationship between PV and canine SCC
with contradictory results (7, 8). To date, the causative role of PV
cannot be totally excluded.
Clinical signs of digital SCC mainly include digital swelling
and lameness, but SCC may mimic a wide variety of other
diseases, such as bacterial, fungal or protozoal pyogranulomatous
infections, epithelial inclusion cysts, infundibular keratinizing
acanthoma, and other benign tumors (9). This frequently causes
misdiagnosis and late presentation, possibly contributing to an
underestimation of its incidence. Referral to a specialist is often
made only after failure of medical management or repeated
surgical attempts by first opinion veterinarians.
Digital SCC usually affects large breed dogs with dark hair
coat (10), with Standard Poodles, black Labrador Retrievers,
Giant Schnauzers, Gordon Setters, Rottweilers, Beaucerons, and
Briards being pre-disposed to multiple lesions (10–12).
Bone lysis occurs in 80% of dogs (1), and digit amputation
is therefore the treatment of choice (1, 13). Nodal or distant
metastasis at admission is reported in <15% of dogs (1,
14); however, no recommendation regarding adjuvant medical
treatment is currently available.
According to the published studies, dogs undergoing digit
amputation will have a 1- and 2-year survival rates of 50–83% and
18–62%, respectively (1, 2, 14). The wide range of survival rates
translates into an objective difficulty in communicating with the
owner. In one study, dogs with SCC arising from the subungual
epithelium experienced a better outcome (14), with 1- and 2-year
survival rates of 95 and 74%, respectively.
Because of the rarity of this cancer, there are only a few
clinical studies that focused specifically on digital SCC, and
the latest dates back to 2007 (2). Since then, no changes
regarding staging work-up and treatment recommendations have
been implemented.
The aim of this retrospective observational study was to report
our experience regarding the clinical presentation, diagnostic
work-up, treatment and outcome of 79 dogs with digital SCC.
MATERIALS AND METHODS
Members of the Italian Society of Veterinary Oncology
(SIONCOV) were asked to retrospectively search their records
to identify dogs with newly diagnosed digital SCC without
any previous surgery or cytotoxic treatment history for the
disease. To be enrolled, dogs had to have a complete staging
work-up, including regional lymph node assessment (either by
cytology or histology), thoracic radiographs, digit radiographs,
and abdominal ultrasound or total body computed tomography
(TBCT), have undergone surgery, and have a complete follow-
up assessed by clinical examinations or phone calls to the
referring veterinarians or owners. Adjuvant cytotoxic treatment
was allowed and documented. Medical records had to be
sufficient to assess treatmentmodalities and to evaluate treatment
response (15).
For each dog, the following data were recorded: signalment
(breed, hair coat color, sex, age, weight), clinical signs and
duration of signs, whether the lesion involved one or multiple
digits, site of involvement, ulceration, bone lysis, type of staging
work-up performed, type of treatment, clinical response to
treatment, time to progression (TTP), time to new digital lesions
(TDG), survival time (ST), and cause of death.
STATISTICAL ANALYSIS
Descriptive statistics were used in the analysis of dogs and
tumor characteristics. When appropriate, data were tested for
normality by use of the D’Agostino and Pearson omnibus
normality test. Values were expressed as mean ± SD in case
of normal distribution, or as median with a range in case of
non-normal distribution.
TTP was calculated from the date of surgery to the to the date
of first-documented local recurrence or metastasis, whichever
occurred first. TDG was calculated from the date of surgery to
the date of development of a new digital SCC not contiguous to
the previous location but occurring in another digit. Dogs with
no events at the date of the last visit or death were censored.
ST was calculated from the date of surgery to the date of death
or to the date of the last visit if death did not occur. Only dogs
deceased for SCC-related causes were considered as events.
Survival plots were generated according to the Kaplan-Meier
product-limit method. Survival estimates were presented as
medians with the corresponding 95% confidence intervals (95%
CI). The influence of potential prognostic variables on tumor
progression, de novo SCC development or SCC-related death was
investigated with Cox’s regression analysis.
The following variables were investigated for prognostic
significance: breed (Schnauzers vs. others), sex, age (median
used as cut-off), weight (median used as cut-off), clinical
signs duration (median used as cut-off), number of lesions at
presentation (single or multiple), limb (forelimb or hindlimb),
subungual location (yes or no), ulceration (yes or no), largest
tumor diameter (median used as cut-off), bone lysis (yes or no),
metastases at diagnosis (yes or no), lymphadenectomy (yes or no)
and adjuvant medical treatment (yes or no).
Statistical analysis was performed with SPSS Statistics v.19
(IBM, Somers, New York). Significance was set at P ≤ 0.05.
RESULTS
Patient and Tumor Characteristics
Medical records of dogs with digital SCC between January 2008
and December 2018 at 8 institutions were evaluated. A total of
79 dogs fulfilled the inclusion criteria and were included in the
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study (n = 27 at University of Bologna; n = 17 at University of
Turin; n= 9 at DickWhite Referrals; n= 9 at Clinica Veterinaria
Tibaldi; n = 7 at University of Zurich; n = 5 at University of
Liverpool; n= 3 at Centro Veterinario BMVET; and n = 2 at
Pronto Soccorso Veterinario Laudense).
Demographic information is reported in Table 1.
Reasons for referral were lameness (n = 46, 58.2%), digital
swelling (n= 22; 7.8%), breaking or splitting of the toenail (n= 8;
12.5%), pain (n = 5; 6.3%), licking at the digit (n = 6; 7.5%), and
bleeding from the digit (n = 4; 5%). Furthermore, 2 (2.5%) dogs
had cutaneous metastatic nodules along the lymphatic vessels.
Median symptom duration was 90 days (range, 2–700 days).
At admission, 72 (91.1%) dogs had a single digit involved,
whereas 7 (8.9%) had involvement of multiple digits.
Among dogs with a single SCC, tumors occurred on the
forelimb digits in 44 (61.1%) dogs and on the hindlimb digits
in 28 (39.4%) dogs. Among dogs with multiple SCC, tumors
occurred in one forelimb and in one hindlimb in 5 (71.4%) dogs,
and in two hindlimbs in 2 (28.6%) dogs.
When considering all SCCs (n = 86), the tumors were
distributed as follows: 21 (24.4%) on the second digit, 21 (24.4
%) on the third, 17 (19.8%) on the fifth, 14 (16.3%) on the fourth,
and 13 (15.1%) on the first. Median tumor diameter was 2.3 cm
(range, 1–6 cm).
Forty-seven (61.8%) tumors were ulcerated, while 29 (38.2%)
were not. This information was not available for 3 (3.8%) dogs.
All dogs underwent cytology of the regional lymph node, and
4 (5.1%) had evidence of metastatic disease. Two (2.5%) dogs
had metastatic nodules along the lymphatic vessels confirmed
by cytology.
In regard to the diagnostic imaging work-up, 69 (87.3%) dogs
underwent thoracic radiographs and abdominal ultrasound, and
10 dogs (12.7%) had a TBCT performed. None had evidence of
distant metastasis.
All dogs underwent either radiographs or CT of the affected
digit, and bone lysis was observed in 73 (92.4%) of them.
Treatment and Outcome
Surgery was the primary treatment for all dogs. Seventy-two dogs
with a single lesion involvement underwent digit amputation
(n = 71) or leg amputation due to the extensive soft tissue
involvement (n= 1). Seven dogs withmultiple lesions underwent
amputation of the affected digits.
Surgical and histological margins were considered complete in
all cases.
Based on the histopathology report, 74 tumors (93.7%) were
well-differentiated; 1 (1.3%) was moderately differentiated and 4
(5%) were poorly-differentiated. In 57 (75%) dogs, the ungual bed
was defined to be the origin of the tumor.
Concurrent lymphadenectomy was performed in 39 (49.4%)
dogs. Histopathological evaluation revealed lymph node
metastasis in 10 (25.6%) dogs, including those 4 with cytological
evidence of metastatic disease. Among these 10 dogs, 2 (20%)
had non-subungual SCC.
The overall metastatic rate at the time of presentation was
15.2% (12/79: 10 nodal and 2 cutaneous).
TABLE 1 | Summary of relevant patient and tumor characteristics observed in 79
dogs with digital squamous cell carcinoma.
Sex
Male intact 35 (44.3%)
Male neutered 15 (19%)
Female intact 11 (13.9%)





Labrador retriever 7 (8.9%)






Median age (range) 10 (2–18) years
Median weight (range) 33 (6.5–52) kg
















Moderately differentiated 1 (1.3%)





disease during the follow-up
Yes 14 (17.7%)
No 65 (82.3%)
1-year survival rate 81%
2-year survival rate 60%
*Data non available for all dogs. **Black, brown, black and brown, black and tan.
Seventeen (21.5%) dogs received some form of adjuvant
treatment: 14 (82.4%) dogs were treated with chemotherapy, 2
(11.8%) with radiation therapy and 1 (5.9%) with both.
Chemotherapy protocols varied widely. Six dogs were treated
with weekly intravenous 5-Fluorouracil at the dose of 150
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mg/m2 with a median number of 10 doses (range, 3–27). Five
dogs were treated with an intravenous platinum compound,
consisting of carboplatin (300 mg/m2 every 21 days for 4
cycles; n = 3) or cisplatin (60 mg/m2 every 21 days for 3
cycles; n = 2). Three (21.4%) dogs were treated with oral
metronomic chemotherapy consisting of thalidomide (4 mg/kg
daily), cyclophosphamide (10 mg/m2 daily), and piroxicam (0.3
mg/kg daily). Median treatment duration in these dogs was 6
months (range, 4–7 months).
Dogs undergoing radiation therapy received 3 × 8Gy
fractions (n = 2) or 12 × 4Gy fractions (n = 1). One of them
also received carboplatin at 250 mg/m2 for 4 cycles.
The median follow-up time was 614 days (range, 128–2,370).
Overall, 3 (3.8%) dogs experienced local recurrence after 17,
64, and 150 days. In one of them, the cancer was invading the
bone. None of these dogs received further treatment other than
excision of the primary SCC.
Eighteen (22.8%) dogs developed de novo SCCs after a
median of 190 days (range, 30–1,688). Among them, 6 received
adjuvant medical treatment, consisting of 5-Fluorouracil (n= 3),
carboplatin (n = 1), cisplatin (n = 1), and metronomic therapy
(n= 1).
Fourteen (17.7%) dogs developed metastatic disease during
the follow-up after a median of 266 days (range, 36–1,070).
Metastatic sites included lung (n = 7), regional lymph nodes (n
= 5), skin (n = 1), and kidneys and liver (n = 1). All metastasis
were confirmed by means of cytological evaluation, excluding the
pulmonary, which were supposed based on thoracic radiographs.
Among dogs developing metastases, 7 (50%) already had nodal
metastatic disease at presentation and failed at another site. Only
4 of them had received adjuvant chemotherapy, consisting of
carboplatin (n= 4) and cisplatin (n= 1).
At the end of the study, 24 dogs had died because of
progressive disease after a median of 302 days (range, 10–1,468).
Thirty-one dogs had died due to tumor-unrelated causes
after a median of 745 days (range, 128–2,370) and 24 dogs
were still alive after a median follow-up of 432 days (range,
147–2,254).
Overall, the median TTP and ST time of the dogs in the study
were not reached. The 1- and 2-year survival rates were of 81 and
60%, respectively.
Results of univariable survival analysis are reported inTable 2.
Variables significantly associated with tumor progression
included the duration of symptoms >90 days (HR= 2.4; 95% CI
= 1.1–5.1; P = 0.02), involvement of multiple digits (HR = 2.9;
95% CI = 1–8.5; P = 0.047) and the administration of adjuvant
medical treatment (HR= 4; 95% CI= 1.8–8.4; P = 0.001).
Variables significantly associated with the development of
new digital lesions included involvement of multiple digits at
presentation (HR = 5.8; 95% CI = 1.9–18.1; P = 0.002) and the
administration of adjuvant medical treatment (HR = 4.3; 95%
CI= 1.6–11.3; P = 0.003).
Variables significantly associated with tumor-related death
included presence of metastatic disease at admission (HR = 7.1;
95% CI = 2.4–21.4; P < 0.001), the Schnauzer breed (HR = 3.1;
95% CI = 1.4–7; P = 0.006), and the administration of adjuvant
medical treatment (HR= 2.9; 95% CI= 1.3–6.7; P = 0.012).
On multivariable analysis, only adjuvant medical treatment
retained significance for tumor progression; whereas all the
aforementioned variables confirmed their significance for new
lesion development and tumor-related death (Table 3).
DISCUSSION
Squamous cell carcinoma develops following malignant
transformation of specialized keratinocytes and is the
most common cancer of the digit in dogs (1, 2). Despite
this, no updated literature is available. Here, we report
our experience regarding presentation, biological behavior
and prognosis of dogs with digital SCC, highlighting
the therapeutic approach and giving a better insight into
prognostic factors.
In the current retrospective multicenter study, 79 dogs
with digital SCC were included. Based on our findings, we
confirm that dark-coated dogs were over-represented similarly
to earlier findings, with Schnauzers representing approximately
one third of the population, further implicating a possible
familial association and/ or genetic pre-disposition as previously
described (12, 16, 17). Additionally, according to the univariate
analysis, the Schnauzer breed was linked to a higher risk of
tumor-specific death compared with all other breeds. The reason
behind this remains unknown. Schnauzers did not have any
apparent poor prognostic factors at presentation, therefore the
clinical behavior may be influenced by breed, as documented
for other tumors such as mast cell tumors (18). Conversely, the
association may just be a coincidental finding.
Similarly to previous reports (1), the majority of SCCs
occurred in the front limbs (61% of cases), although they can
develop in any digit.
It has been previously documented that subungual SCCs
are associated with a better outcome (14). In the current case
series, 75% of dogs had their SCC arising from the subungual
epithelium, yet this was not linked to a longer survival. The small
number of dogs having their SCC arising at sites different from
the nail bedmay have prevented a possible prognostic association
to emerge.
At admission, ∼9% of dogs had multiple digit involvement,
and this was associated with a shorter TTP and with the
development of new digital lesions. Synchronous SCCs are an
exceptional presentation in people (<4% of cases) (19), with
trauma, PV infection and occupational exposure possibly acting
as predisposing risk factors in some cases (4).
In past studies, presence or development of new digital lesions
was mentioned in 3/33 dogs with SCC according to one study
(1); 13/154 had multiple digit involvement at presentation and
11/49 developed de novo digital lesions in other digits according
to another (10). However, no risk factors were identified (1, 10).
The finding that multiple digit involvement poses a higher risk is
therefore new and important. Owners should be informed that—
if synchronous lesions are present—their dogs may develop
further lesions in the future.
Additional dogs and tumor variables such as sex, age,
weight, ulceration, tumor diameter, and bone lysis did not show
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TABLE 2 | Univariable Cox regression analysis of variables potentially associated with increased risk of tumor progression, de novo tumor development and survival time
in 79 dogs with digital squamous cell carcinoma.
Variable Tumor progression Development of new digital lesions Tumor-related death
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Breed 1.8 (0.9–3.7) 0.113 2 (0.8–5) 0.159 3.1 (1.4–7) 0.006*
Schnauzer
Other**
Sex 1.9 (0.8–4.2) 0.134 1.8 (0.6–5) 0.282 1.5 (0.6–3.6) 0.363
Male
Female**
Agea 1.4 (0.6–2.8) 0.410 1.3 (0.5–3.4) 0.561 2.1 (0.8–4.9) 0.094
≤10 years**
>10 years
Weighta 1 (0.5–2.1) 0.967 0.7 (0.3–1.7) 0.407 0.9 (0.4–2.1) 0.877
≤32 kg**
>32 kg
Duration of symptomsa 2.4 (1.1–5.1) 0.02* 2.4 (0.9–6.3) 0.081 1.8 (0.8–4.2) 0.141
≤90 days**
>90 days
Presentation 2.9 (1–8.5) 0.047* 5.8 (1.9–18.1) 0.002* 2 (0.7–5.9) 0.199
Single**
Multiple
Subungual 3 (0.9–10) 0.072 5.4 (0.7–40.7) 0.104 1.4 (0.5–4.3) 0.511
Yes
No**
Ulceration 1.3 (0.6–2.9) 0.467 1.1 (0.4–2.9) 0.811 1.8 (0.7–4.4) 0.216
Yes
No**
Tumor diametera 1.5 (0.6–4.2) 0.391 1.5 (0.4–5.5) 0.559 1.1 (0.4–3.1) 0.839
≤2.3 cm**
>2.3 cm
Bone lysis 0.9 (0.2–4) 0.930 1.2 (0.2–9.5) 0.830 0.7 (0.1–3.0) 0.628
Yes
No**
Metastasis at admission 2.2 (0.5–9.1) 0.294 0.5 (0 ≥ 100) 0.627 7.1 (2.4–21.4) <0.001*
Yes
No**
LNctomy 1.2 (0.6–2.6) 0.568 1.2 (0.5–3.1) 0.660 1.6 (0.7–3.6) 0.287
Yes
No**
Adjuvant medical treatment 4 (1.8–8.4) 0.001* 4.3 (1.6–11.3) 0.003* 2.9 (1.3–6.7) 0.012*
Yes
No**
LNctomy, lymphadenectomy; HR, hazard rato; CI, confidence interval. aMedian used as cut-off value. *Significant. **Reference category.
statistically significant impact on TTP, development of new
digital lesions and ST.
Digital SCC can be difficult to diagnose because its
presentation can mimic other conditions (9). A duration of
symptoms >90 days was significantly associated with higher risk
for tumor progression. The diagnostic delay is common because
clinical signs are initially mild and may be disregarded at first.
Also, as anticipated, clinical similarities to many inflammatory
and benign neoplastic conditionsmay cause diagnostic confusion
and further delay in diagnosing the disease. Indeed, digital
SCC often presents with non-specific clinical features such as
pain, disruption of the nail, ulceration, periungual or subungual
mass, paronychia, destruction of the nail or onychomadesis.
As a consequence, the delay in diagnosis could lead to more
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TABLE 3 | Multivariable Cox regression analysis of variables potentially associated
with increased risk of tumor progression, de novo tumor development and survival
time in 79 dogs with digital squamous cell carcinoma.
Covariates HR (95% CI) P












Adjuvant medical treatment 3.4 (1.2–9.4) 0.019*
Tumor-related
death
Schnauzer breed 3.9 (1.7–9.2) 0.002*
Metastasis at admission 5.8 (1.8–18) 0.002*
Adjuvant medical treatment 2.8 (1.2–6.9) 0.021*
HR, hazard rato; CI, confidence interval. aMedian used as cut-off value. *Significant.
advanced disease states or higher metastatic rate at presentation
and could be a reason why the longer duration of clinical signs
was associated with a worse outcome.
Although chronic inflammation and infections have
been suggested as etiological factors triggering neoplastic
transformation in human SCC (20), thereby triggering neoplastic
transformation, it remains unclear whether the same holds true
for dogs with digital SCC.
Regardless, a biopsy in every digit abnormality not responding
to initial treatment should be carried out to avoid delays in
diagnosis and subsequent treatment. Radiographs should also
be obtained, as bone involvement occurred in >90% of dogs
in the current series population and helps guide the extent
of surgery.
The overall metastatic rate at admission was 15.2%, in
line with the published literature, and none of the dogs had
distant metastasis (1, 14). Thoracic radiographs and abdominal
ultrasound were carried out in the majority of dogs, highlighting
that there is little evidence on the need for advanced imaging
investigations to detect metastases in digital SCC. Based on the
previous and current findings, digital SCC can most likely be
considered as a malignancy with a low tendency to metastasize
if treated adequately. Nevertheless, assessment of the regional
lymph nodes as routine examination should be performed.
All dogs in the current study underwent cytological evaluation
of the regional lymph node, and 4 (5.1%) had evidence of
metastatic disease. Approximately 50% of dogs also underwent
lymphadenectomy, and metastatic disease was detected in 6
additional dogs, leading to an overall nodal metastatic rate at
presentation of 12.7%. This finding emphasizes the need for
nodal histopathological evaluation to detect metastasis, as nodal
metastases worsened outcome in the current case series. Also,
cytology might not be able to rule out early metastatic disease in
all cases.
Lymphadenectomy per se did not show any statistically
significant impact on TTP, development of new digital lesions
and ST, thereby not having a therapeutic implication. However,
it must be acknowledged that 50% of dogs did not have the
regional lymph node removed, possibly contributing to an
outcome bias. Future prospective studies must address whether
lymphadenectomy of metastatic nodes improves survival.
Given the rarity of digital SCC, there is no consensus on
the optimal treatment. No standardized therapeutic approach is
described in SCC, and the choice is selected on the basis of the
extent of the tumor.
Complete surgical excision was obtained in all dogs; there
were 3 (3.8%) cases with local recurrence after amputation. Thus,
it appears that digit amputation may achieve adequate local
tumor control in the majority of cases.
Adjuvant treatments, including chemotherapy and radiation
therapy, were only carried out in 21.5% of dogs. According
to our data analysis, adjuvant chemotherapy was associated
with a worse outcome. It is plausible that this is a selection
bias, with dogs with more extensive disease and thus a worse
prognosis more likely treated with chemotherapy. Due to the
relatively non-aggressive clinical behavior and low metastatic
rate, chemotherapy should most likely only be offered in the case
of metastatic disease. Nevertheless, the best protocol has not been
established yet.
Eighteen (22.8%) dogs developed de novo SCCs during
the follow-up period. Thus, owners need to be instructed to
check their dog’s nails routinely and to seek for professional
guidance as soon as any clinical changes are noted. Moreover,
careful examination of the digits upon annual veterinary
check-ups should be encouraged for breeds at high risk for
digital SCC.
Overall, 17.7% of dogs developedmetastatic disease during the
follow-up; half of them had nodal metastasis at admission. It may
be concluded that dogs with lymph node metastasis are at risk for
further metastases and should be monitored more closely.
In line with the published literature, the 1- and 2-year survival
rates in the current study were of 81 and 60%, respectively,
whereas the median TTP and ST time were not reached.
This study has several limits, mainly attributable to its
retrospective nature.
Different imaging modalities were carried out during the
initial staging work-up, and it may be possible that pulmonary
metastases were missed in those cases undergoing thoracic
radiographs. Nevertheless, the long follow-up would have made
it possible to identify dogs with lung metastases.
Lymphadenectomy was only performed in 50% of dogs,
thereby precluding to draw any meaningful conclusions
regarding its therapeutic role. Also, adjuvant treatment was
not standardized, and the motivation behind the choice as to
whether or not administering chemotherapy was unclear.
None of the cases had review of the histopathological findings,
therefore precluding us from identifying other variables that
may help in predicting cases prone to more aggressive biological
behavior. Immunohistochemical assessment of adhesin molecule
such as E-cadherin, β-catenin and desmoglein in combination
with invasive front grading of the tumor, may be used to
predict the biological behavior of canine oral and cutaneous
SCC (21). In the aforementioned study, higher histological grade
was associated with a more aggressive biologic behavior. In
Frontiers in Veterinary Science | www.frontiersin.org 6 April 2021 | Volume 8 | Article 645982
Marconato et al. Digital SCC in Dogs
the current study, immunohistochemistry was not performed in
any case.
Nevertheless, only 4 SCCs were classified as poorly
differentiated. Considering the above, the utility of
immunohistochemistry in predicting the biological behavior of
digital SCC in the present study is questionable.
This study, however, is unique in that only those cases
that had a complete work-up, an accurate treatment and
outcome description and an adequate follow-up were included
in the analysis.
In conclusion, the diagnosis of digital SCC can be challenging,
as it is often delayed by the presence of clinical signs non-
specific of neoplasia, encompassing a variety of differential
diagnosis of nail and limb pathologies. Although, metastases
remain rare with prolonged TTP and disease-specific ST, non-
resolving digit and nail conditions, especially if present in dark-
coated dogs, should raise the suspicion of digital SCC and
investigations should be directed accordingly. Multiple lesions
and nodal involvement at diagnosis are associated with a poorer
outcome. Schnauzers remain a predisposed breed and with the
potential of a poorer clinical outcome, whereas non-subungual
origin did not seem to impact outcome in this cohort of
patients. Digital amputation is still the treatment of choice and
the majority of dogs will benefit from a surgical procedure as
single treatment modality. Regional lymphadenectomy can offer
important prognostic information and we advise to include this
in the surgical treatment plan.
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